Scientific deep-dive
The Fat Pads in Your Ears
Your eustachian tube is held closed partly by fatty cushions. Two cases describe it staying open after weight loss on a GLP-1 — and the adverse event database records the symptom zero times.
Your eustachian tube is held closed partly by small fatty cushions. Lose enough fat and it can stay open — which makes your own voice and breathing boom inside your head. Two published cases describe exactly that after starting a GLP-1, with endoscopy confirming the cushions had thinned.[1] Then the authors searched the FDA’s adverse event database and found the symptom reported zero times.
The mechanism, which is genuinely elegant
The eustachian tube connects the middle ear to the back of the throat and equalizes pressure. It is normally shut, opening briefly when you swallow or yawn. Part of what keeps it shut is bulk in the surrounding tissue, including fat.
When that bulk is lost, the tube can become patulous — stuck open. The result is autophony: your own voice, your breathing, sometimes your heartbeat, transmitted directly into the middle ear. People describe it as speaking into a barrel. It is not dangerous and it is genuinely unpleasant, and it is a known consequence of rapid weight loss from any cause.
In the two cases reported here, nasal endoscopy confirmed significant loss of tissue bulk in the anterior and posterior cushions of the tube. That is not an inference — someone looked.
The check that did not confirm it
| Event | Reports |
|---|---|
| Hypoacusis (reduced hearing) | 515 |
| Vertigo | 203 |
| Deafness | 97 |
| Tinnitus | 93 |
| Ear pain | 22 |
| Motion sickness | 21 |
| Hyperacusis | 5 |
| Ear fullness | 2 |
| Autophony | 0 |
Note also what dominates that list. More than half of all otologic reports are hypoacusis — reduced hearing — which is a different problem from a tube that will not close, and would not be produced by the mechanism described above.
Why publishing both halves is the right thing to do
A beautiful mechanism plus two cases is a hypothesis. The database was the test.
It would have been easy to publish the cases and the anatomy and stop. The mechanism is coherent, the endoscopy is convincing, and nobody would have checked. Reporting the zero alongside them is what makes this a useful paper rather than a persuasive one.
So the honest verdict is that this is unresolved. A specific, visible, anatomically confirmed mechanism exists in two people. Whether it happens at any meaningful rate is not answerable from a database that would probably not capture it.
One further oddity, consistent with something we have found before: the largest count of potentially tube-related events belongs to dulaglutide, at 417 — not to the drugs producing the most weight loss and attracting the most attention. If fat loss around the tube were driving this, that is not the ranking you would expect.
What to do if this is happening to you
- It is not dangerous, and it is not imaginary. Patulous eustachian tube dysfunction is a recognized condition with a recognized cause.
- It often improves as weight stabilizes, since it is driven by change rather than by a level.
- An ear, nose and throat clinician can see it — the endoscopy in these cases showed the tissue directly, so this is a symptom with an objective finding behind it.
- Say what you take. The connection is obscure enough that a clinician may not raise it, and rapid weight loss is the relevant history.
It is worth saying plainly that this is a minor problem in a field full of major ones. It appears here because a symptom with a mechanism and no reports is a good example of how to hold an uncertain finding — and because someone experiencing it is currently unlikely to find anything written about it at all.
Frequently Asked Questions
References
- 1.Pak KY, Cutri RM, Nadeem W, et al. GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events Otology & Neurotology. 2025. PMID: 39666743.
Related research
Taste Got Better, Not Worse
People on these drugs routinely say food tastes wrong. A trial measured taste objectively, biopsied participants' tongues and scanned their brains — and found taste recognition improved.
6 min read
Uric Acid and Two Answers
Two studies asked whether these drugs lower uric acid. Both said yes. One found the effect 72.7% explained by weight loss; the other found it independent of weight loss entirely.
7 min read
What These Hormones Do Without a Pancreas
To isolate what the gut hormones do outside the pancreas, researchers studied twelve people who no longer have one — and blocked the receptors. The one clear result was about bone.
6 min read
A Biomarker Is Not an Outcome
Sixteen cardiovascular risk markers were measured in SURMOUNT-1 at 72 weeks, and most improved substantially. Cardiology has learned twice, expensively, why that is not the same as preventing events.
8 min read
A Weight Drug for Having Too Little Fat
Lipodystrophy is the opposite of obesity — people are missing fat tissue, and are severely metabolically ill because of it. A cohort given tirzepatide cut their daily insulin by a median of 109 units.
6 min read
Five Hundred Calories at One Lunch
Researchers weighed what 114 people ate at a free-access lunch. Three weeks into tirzepatide they ate 524.6 fewer calories — without any increase in conscious dietary restraint.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Gala
Moving between compounded and brand without changing seller
Pricing Compare
Get started →Trimi Health
Knowing which pharmacy fills the vial — it names VialsRx
Pricing Compare
Get started →ShedRx
Oral orforglipron alongside the injectables
Pricing Compare
Get started →